GlassScriptPhysician profile
James Byron Shipp
NPI 1427212992
$20,615.44
in general payments reported to CMS, 2019-2025
31 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $144 · 2021: $303 · 2022: $17K · 2023: $922 · 2024: $508 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Travel and Lodging: $931 · Entertainment: $25.85 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.05 |
| Travel and Lodging | $930.93 |
| Entertainment | $25.85 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $16,851.08 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $1,365.47 | 2019-2025 | Clareon, Unity, Wavelight Refractive Suite |
| Mallinckrodt Hospital Products INC. | $864.27 | 2021-2025 | Acthar |
| Allergan, INC. | $201.82 | 2019-2021 | |
| Amgen INC. | $193.65 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $188.45 | 2020-2025 | Dextenza |
| Horizon Therapeutics Plc | $104.07 | 2022-2023 | |
| Abbvie INC. | $91.11 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Ivantis, INC | $76.22 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $72.39 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $69.93 | 2022-2023 | |
| Sight Sciences, INC. | $50.60 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $50.09 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $50.03 | 2023-2025 | Xiidra, Miebo, Scoutpro Osmolarity System |
| Johnson & Johnson Vision Care, INC. | $39.00 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $33.19 | 2021-2024 | Misight Contact Lens |
| Genentech USA, INC. | $31.81 | 2019-2022 | |
| Glaukos Corporation | $28.29 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $26.36 | 2022 | |
| Dompe US, INC. | $25.86 | 2022 | |
| Nova Eye, INC. | $25.85 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $25.26 | 2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $24.62 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.20 | 2020 | |
| New World Medical,INC. | $17.15 | 2025 | Kahook Dual Blade, Via360, Clearpath |
| Rayner Intraocular Lenses Limited | $16.82 | 2022 | |
| Mindray Ds USA, INC. | $15.70 | 2024 | A7 Anesthesia System |
| Novartis Pharmaceuticals Corporation | $14.68 | 2023 | |
| Beaver-Visitec International, INC. | $12.46 | 2019 | |
| Eyepoint US, INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.